Fulcrum Therapeutics (FULC) Share-based Compensation (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Share-based Compensation data on file, last reported at $3.9 million in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $3.9 million, up 21.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.2 million (down 4.66% YoY), and the FY2025 annual result was $12.5 million, down 14.33% from the prior year.
• Share-based Compensation advanced to $3.9 million in Q1 2026 per FULC's latest filing, from $3.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $4.3 million in Q2 2024 and troughed at $2.5 million in Q4 2024.
• A 5-year average of $3.5 million and a median of $3.4 million in 2023 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2022 and 2025: Share-based Compensation soared 85.58% in 2022, then slumped 33.82% in 2025.
• A 5-year view of Share-based Compensation shows it stood at $3.3 million in 2022, then increased by 5.44% to $3.4 million in 2023, then retreated by 28.18% to $2.5 million in 2024, then increased by 23.78% to $3.1 million in 2025, then gained by 25.9% to $3.9 million in 2026.
• Business Quant data shows FULC's Share-based Compensation at $3.9 million in Q1 2026, $3.1 million in Q4 2025, and $3.4 million in Q3 2025.